MNLpharma Ltd (MNL) announces today that, in conjunction with Cambridge BioStability Ltd (CBL), and the University of Cambridge, it has received a major grant award from the DTI to develop controlled-release nanoparticle vaccines. The DTI is providing a grant of £1.5 million over three years. With the project partners providing matching funds, bringing the total investment in the programme will be £3.1 million.
